ArticleAnnals of translational medicine2022
Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Case Report: Dostarlimab for treatment of aggressive cutaneous squamous cell carcinoma.Frontiers in medicine · 2024Article
- Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy.Drug design, development and therapy · 2023Article
- Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor-infiltrating immune cells are instrumental in the spread, resurgence, metastasis, and immunotherapy responsiveness of endometrial cancer (EC), which is a prevalent, malignant gynecologic tumor with a dismal prognosis. Many questions remain about the safety and effectiveness of immunotherapy, so we investigated both the patients' immunological condition and the molecular subtypes of EC. Methods: Relevant data sets were collected from the The Cancer Genome Atlas (TCGA), and the CIBERSORT and ESTIMATE methods were used to assess the immune microenvironment and immune cell infiltration (ICI) in uterine corpus EC (UCEC) tumors. Using the immunophenoscore (IPS), the differentially expressed genes between low and high IPS were identified, and the immune gene subtypes of UCEC were further explored. Based on the main effect genes among the immune molecular subtypes, a tumor ICI scoring model was constructed. Results: There was individual heterogeneity in the characteristics of ICI in the tumor samples, and these characteristics were associated with overall survival (OS). The IPS was quantified by the pattern of gene differential expression, and five immune molecular subtypes were constructed. The levels of PD1/PD-L1 expression in these subtypes showed significant differences, and there were also differences in gene mutation profiles between low- and high-ICI scores. Conclusions: The ICI score of UCEC samples can be used to predict the benefit of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.